SAN DIEGO--(BUSINESS WIRE)--Tear Film Innovations, Inc. (TFI) announced today it has completed a $8.5 million Series B Preferred Stock funding round led by Visionary Ventures Fund, L.P. and Bluestem ...

Handheld and portable, the iLux Device enables eye care professionals to directly target a patient's blocked meibomian glands and provide therapy through an in-office treatment. Using the iLux Device, ...

Alcon plans to further expand availability of this technology throughout the U.S. and Canada in early 2019. Fort Worth, Texas December 19, 2018 - Alcon, the global leader in eye care and a division of ...

Meeting attendees will also have the opportunity to receive a hands-on experience with the iLUX device and learn more about Alcon’s practice implementation program, DEEP™ (Dry Eye Excellence Program), ...

Tear Film Innovations has raised $8.5 million in series B financing as the company plans to bring on additional staff to continue development of its iLux device treatment for evaporative dry eye and ...

Please provide your email address to receive an email when new articles are posted on . Tear Film Innovations has announced the successful completion of its Series B Preferred Stock funding round, ...

Fort Worth, Texas December 19, 2018 - Alcon, the global leader in eye care and a division of Novartis, today announced that it has acquired Tear Film Innovations, Inc. ("Tear Film"), a privately-held ...

Please provide your email address to receive an email when new articles are posted on . Tear Film Innovations has completed $8.5 million in Series B funding, the company announced in a press release.